Related references
Note: Only part of the references are listed.Impact of Probe Substrate Selection on Cytochrome P450 Reaction Phenotyping Using the Relative Activity Factor
Y. Amy Siu et al.
DRUG METABOLISM AND DISPOSITION (2017)
CYP2C9 Genotype-DependentWarfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R-and S-Warfarin and Their Oxidative Metabolites
Darcy R. Flora et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Utilization of Liver Microsomes to Estimate Hepatic Intrinsic Clearance of Monoamine Oxidase Substrate Drugs in Humans
Yusuke Masuo et al.
PHARMACEUTICAL RESEARCH (2017)
Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic Clearance
Daniel Scotcher et al.
DRUG METABOLISM AND DISPOSITION (2017)
Clearance Prediction of Targeted Covalent Inhibitors by In Vitro-In Vivo Extrapolation of Hepatic and Extrahepatic Clearance Mechanisms
Louis Leung et al.
DRUG METABOLISM AND DISPOSITION (2017)
Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction Metabolized
Stephen Fowler et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review
C. M. Nijenhuis et al.
DRUG METABOLISM REVIEWS (2016)
Novel Cytochrome P450 Reaction Phenotyping for Low-Clearance Compounds Using the Hepatocyte Relay Method
Xin Yang et al.
DRUG METABOLISM AND DISPOSITION (2016)
Determination of Human Hepatocyte Intrinsic Clearance for Slowly Metabolized Compounds: Comparison of a Primary Hepatocyte/Stromal Cell Co-culture with Plated Primary Hepatocytes and HepaRG
Britta Bonn et al.
DRUG METABOLISM AND DISPOSITION (2016)
Upcyte Human Hepatocytes: a Potent In Vitro Tool for the Prediction of Hepatic Clearance of Metabolically Stable Compounds
Michelle Schaefer et al.
DRUG METABOLISM AND DISPOSITION (2016)
Prediction of Drug Clearance and Drug-Drug Interactions in Microscale Cultures of Human Hepatocytes
Christine Lin et al.
DRUG METABOLISM AND DISPOSITION (2016)
Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective
Tonika Bohnert et al.
DRUG METABOLISM AND DISPOSITION (2016)
Addressing the Challenges of Low Clearance in Drug Research
Li Di et al.
AAPS JOURNAL (2015)
The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects
Huiping Xu et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors
Michael A. Brodney et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Application of C-14-Accelerator MS in pharmaceutical development
Graeme C. Young et al.
BIOANALYSIS (2015)
Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device
Aurelie Vivares et al.
XENOBIOTICA (2015)
Metabolism, excretion and pharmacokinetics of [C-14]crizotinib following oral administration to healthy subjects
Theodore R. Johnson et al.
XENOBIOTICA (2015)
A Long-Standing Mystery Solved: The Formation of 3-Hydroxydesloratadine Is Catalyzed by CYP2C8 But Prior Glucuronidation of Desloratadine by UDP-Glucuronosyltransferase 2B10 Is an Obligatory Requirement
Faraz Kazmi et al.
DRUG METABOLISM AND DISPOSITION (2015)
A UGT2B10 Splicing Polymorphism Common in African Populations May Greatly Increase Drug Exposure
Stephen Fowler et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Reaction Phenotyping: Advances in the Experimental Strategies Used to Characterize the Contribution of Drug-Metabolizing Enzymes
Michael A. Zientek et al.
DRUG METABOLISM AND DISPOSITION (2015)
The effect of pathophysiology on pharmacokinetics in the critically ill patient - Concepts appraised by the example of antimicrobial agents
Stijn I. Blot et al.
ADVANCED DRUG DELIVERY REVIEWS (2014)
Contribution of cytochrome P450 and UDT-glucuronosyltransferase to the metabolism of drugs containing carboxylic acid groups: risk assessment of acylglucuronides using human hepatocytes
Norimasa Jinno et al.
XENOBIOTICA (2014)
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans
Martin E. Dowty et al.
DRUG METABOLISM AND DISPOSITION (2014)
Disposition and Metabolism of Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Humans
Mehul Dave et al.
DRUG METABOLISM AND DISPOSITION (2014)
Disposition and Metabolic Profiling of [14C]Cerlapirdine Using Accelerator Mass Spectrometry
Susanna Tse et al.
DRUG METABOLISM AND DISPOSITION (2014)
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME
Patricio Godoy et al.
ARCHIVES OF TOXICOLOGY (2013)
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Ulrich M. Zanger et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans
Christopher R. Gibson et al.
XENOBIOTICA (2013)
Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac
Tom S. Chan et al.
DRUG METABOLISM AND DISPOSITION (2013)
In Vitro-In Vivo Correlation for Low-Clearance Compounds Using Hepatocyte Relay Method
Li Di et al.
DRUG METABOLISM AND DISPOSITION (2013)
Disposition and Metabolism of GSK2251052 in Humans: A Novel Boron-Containing Antibiotic
Gary D. Bowers et al.
DRUG METABOLISM AND DISPOSITION (2013)
A Novel Relay Method for Determining Low-Clearance Values
Li Di et al.
DRUG METABOLISM AND DISPOSITION (2012)
Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite
Xavier Boulenc et al.
DRUG METABOLISM AND DISPOSITION (2012)
Clinically Relevant Genetic Variations in Drug Metabolizing Enzymes
Navin Pinto et al.
CURRENT DRUG METABOLISM (2011)
Utility of Intersystem Extrapolation Factors in Early Reaction Phenotyping and the Quantitative Extrapolation of Human Liver Microsomal Intrinsic Clearance Using Recombinant Cytochromes P450
Yuan Chen et al.
DRUG METABOLISM AND DISPOSITION (2011)
Characterization of Human Liver Enzymes Involved in the Biotransformation of Boceprevir, a Hepatitis C Virus Protease Inhibitor
Anima Ghosal et al.
DRUG METABOLISM AND DISPOSITION (2011)
Substrate inhibition kinetics in drug metabolism reactions
Baojian Wu
DRUG METABOLISM REVIEWS (2011)
N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275
Michael Siu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Impact of Infectious and Inflammatory Disease on Cytochrome P450-Mediated Drug Metabolism and Pharmacokinetics
E. T. Morgan
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction
Odette A. Fahmi et al.
DRUG METABOLISM AND DISPOSITION (2009)
Gender and interindividual variability in pharmacokinetics
Jean-Marie Nicolas et al.
DRUG METABOLISM REVIEWS (2009)
Application of CYP3A4 in vitro data to predict clinical drug-drug interactions;: predictions of compounds as objects of interaction
Kuresh A. Youdim et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Modeling, Prediction, and in Vitro in Vivo Correlation of CYP3A4 Induction
Magang Shou et al.
DRUG METABOLISM AND DISPOSITION (2008)
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers
Angela Sansone-Parsons et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Minimizing polymorphic metabolism in drug discovery: Evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism
John P. Gibbs et al.
DRUG METABOLISM AND DISPOSITION (2006)
Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage
C. Emoto et al.
XENOBIOTICA (2006)
Enzyme kinetics for clinically relevant CYP inhibition
ZY Zhang et al.
CURRENT DRUG METABOLISM (2005)
Modelling atypical CYP3A4 kinetics: principles and pragmatism
JB Houston et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2005)
Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs - Clinical relevance
J Kirchheiner et al.
CLINICAL PHARMACOKINETICS (2005)
Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors
NJ Proctor et al.
XENOBIOTICA (2004)
Utility of recombinant enzyme kinetics in prediction of human clearance: Impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates
A Galetin et al.
DRUG METABOLISM AND DISPOSITION (2004)
Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications
AA Mangoni et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Modeling kinetic data from in vitro drug metabolism enzyme experiments
TS Tracy et al.
DRUG METABOLISM REVIEWS (2004)
Atypical enzyme kinetics:: Their effect on in vitro-in vivo pharmacokinetic predictions and drug interactions
TS Tracy
CURRENT DRUG METABOLISM (2003)
Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole
R Hyland et al.
DRUG METABOLISM AND DISPOSITION (2003)
Atypical kinetic profiles in drug metabolism reactions
JM Hutzler et al.
DRUG METABOLISM AND DISPOSITION (2002)
The genetic basis of variability in drug responses
DM Roden et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Enzyme kinetics of cytochrome P450-mediated reactions
M Shou et al.
CURRENT DRUG METABOLISM (2001)
Share Paper
